RESVINET
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23 >
      • RSVVW'23 Home
      • Registration Fees
      • Visa
      • Accommodation
      • Abstract Submission
      • Young Researchers' Tournament
      • Poster Presentation
      • Accreditation
      • Speakers' Information
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23 >
      • RSVVW'23 Home
      • Registration Fees
      • Visa
      • Accommodation
      • Abstract Submission
      • Young Researchers' Tournament
      • Poster Presentation
      • Accreditation
      • Speakers' Information
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network

Publications

Maternal influenza vaccination is effective

2/10/2014

0 Comments

 
Madhi SA et al.

Maternal vaccination offers a promising solution to RSV bronchiolitis. Different companies are developing maternal RSV vaccines. For example, Novavax has successfully used a nanoparticle-based RSV-F vaccine in a phase 2 trial in women of child bearing age. The potential efficacy of maternal vaccination is now beautifully shown by Madhi and colleagues showing that maternal vaccination may be effective to prevent severe infectious diseases during infancy.

In a large influenza trial, maternal vaccination with a trivalent inactivated influenza vaccine was about 50% protective against influenza disease in 2116 pregnant women and their babies up to age 24 weeks. A parallel trial in HIV positive pregnant women was performed. Infants of HIV positive mothers showed higher rates of influenza, but vaccine efficacy was reduced to 27%.

This study is relevant to the development of a maternal RSV vaccine, because it provides proof of principle that such a strategy in low income countries may be quite successful. For infants from HIV positive mothers, also those who are born HIV negative, other strategies are required.
Download file
0 Comments

    CATEGORIES

    All
    ReSViNET Publications


    ARCHIVES

    January 2023
    April 2022
    February 2022
    September 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    March 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    December 2017
    May 2017
    March 2017
    February 2017
    September 2016
    June 2016
    March 2016
    November 2015
    October 2015
    September 2015
    June 2015
    May 2015
    April 2015
    March 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014


    RSS Feed

Note: All information on ReSViNET is for educational purposes only. For specific medical advice, diagnoses, and treatment, consult your doctor.

© 2021 ReSViNET Foundation. All rights reserved.
About us
Disclosure
Contact